Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome

Table 2 CMR variables at baseline and follow-up

	Rosiglitazone therapy			Placebo therapy			Rosiglitazone therapy	Placebo therapy
	Baseline	Follow-up	P-value	Baseline	Follow-up	P-value	Δ baseline-follow-up	Δ baseline-follow-up	P-value
CMR variables
LV EDV-I (ml/m²)	91.1 ± 11.8	92.3 ± 5.1	0.7	78.7 ± 6.4 †	80.7 ± 10.7‡	0.5	1.2 ± 10.4	1.9 ± 9.0	0.9
LV ESV-I (ml/m²)	38.3 ± 8.9	36.8 ± 5.0	0.4	32.0 ± 4.5	32.5 ± 7.8	0.8	-1.5 ± 5.9	0.5 ± 6.2	0.5
LV mass-I (g/m²)	54.7 ± 9.9	53.7 ± 9.2	0.3	48.9 ± 5.3	44.3 ± 5.6‡	< 0.001	-1.0 ± 2.5	-4.6 ± 1.9	0.002
LVEF (%)	58.1 ± 6.7	60.1 ± 4.9	0.095	59.3 ± 4.4	60.0 ± 5.7	0.6	2.0 ± 3.3	0.7 ± 3.9	0.4

† p < 0.05 between subjects who received rosiglitazone or placebo therapy at baseline.
‡ p < 0.05 between subjects who received rosiglitazone or placebo therapy at follow-up.
LV EDV-I: left ventricular end-diastolic volume indexed for body surface area, LV ESV-I: left ventricular end-systolic volume indexed for body surface area: LV mass-I: left ventricular mass indexed for body surface area, left ventricular, LVEF: left ventricular ejection fraction.

ISSN: 1532-429X